bioAffinity Technologies, Inc. (BIAF)
(Delayed Data from NSDQ)
$0.30 USD
-0.01 (-1.94%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $0.30 0.00 (0.67%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BIAF 0.30 -0.01(-1.94%)
Will BIAF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BIAF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIAF
The Zacks Analyst Blog Highlights Meta Platforms, ServiceNow, Booking, Vaso and bioAffinity Technologies
Top Research Reports for Meta Platforms, ServiceNow & Booking
BIAF: What are Zacks experts saying now?
Zacks Private Portfolio Services
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline
The Zacks Analyst Blog Highlights Alphabet, Berkshire Hathaway, Visa and bioAffinity Technologies
Top Stock Reports for Alphabet, Berkshire Hathaway & Visa
Other News for BIAF
BIAF Gains Canadian Patent for Innovative Lung Disease Detection Method | BIAF Stock News
BioAffinity Technologies awarded new Canadian patent for CyPath Lung